Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial

被引：0
|
作者：
Yongliang Feng
Jing Chen
Tian Yao
Yue Chang
Xiaoqing Li
Rongqin Xing
Hong Li
Ruixue Xie
Xiaohong Zhang
Zhiyun Wei
Shengcai Mu
Ling Liu
Lizhong Feng
Suping Wang
机构：
[1] Shanxi Medical University,Department of Epidemiology, School of Public Health
[2] Shanxi Medical University,Center of Clinical Epidemiology and Evidence Based Medicine
[3] Shanxi Provincial Center for Disease Control and Prevention,undefined
[4] Shanxi Provincial Key Laboratory for Major Infectious Disease Response,undefined
[5] Outpatient Department of Shanxi Aviation Industry Group Co. LTD,undefined
来源：
Infectious Diseases of Poverty | / 10卷
关键词：
COVID-19; Inactivated SARS-CoV-2 vaccine; Immunogenicity; Safety; High-risk occupational population; Randomized controlled trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults
    Yassini, Patrick
    Hutchens, Mark
    Paila, Yamuna D.
    Schoch, Lorraine
    Aunins, Anne
    Siangphoe, Uma
    Paris, Robert
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (01)
  • [32] A survey on the safety of the SARS-CoV-2 vaccine among a population with stroke risk in China
    Wu, Gang
    Zhang, Meixian
    Xie, Xiaomei
    Zhu, Yanwu
    Tang, Hongxia
    Zhu, Xinmiao
    Liang, Yifan
    Chen, Tao
    Zhu, Kuangyao
    Zhang, Danfeng
    Jiang, Sujun
    Jiang, Zhengli
    Ke, Shaofa
    FRONTIERS IN MEDICINE, 2022, 9
  • [33] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial
    Guo, Wanshen
    Duan, Kai
    Zhang, Yuntao
    Yuan, Zhiming
    Zhang, Yan-Bo
    Wang, Zejun
    Zhao, Dongyang
    Zhang, Huajun
    Xie, Zhiqiang
    Li, Xinguo
    Peng, Cheng
    Zhang, Wei
    Yang, Yunkai
    Chen, Wei
    Gao, Xiaoxiao
    You, Wangyang
    Wang, Xue-Wei
    Shi, Zhengli
    Wang, Yanxia
    Yang, Xu-Qin
    Zhang, Lianghao
    Huang, Lili
    Wang, Qian
    Lu, Jia
    Yang, Yong-Li
    Guo, Jing
    Zhou, Wei
    Wan, Xin
    Wu, Cong
    Wang, Wenhui
    Du, Jianhui
    Nian, Xuanxuan
    Li, Xing-Hang
    Huang, Shihe
    Shen, Shuo
    Xia, Shengli
    Pan, An
    Yang, Xiaoming
    ECLINICALMEDICINE, 2021, 38
  • [34] Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial
    Jin, Fei
    Qiu, Yuanzheng
    Wu, Zhiwei
    Wang, Yuan-Hui
    Cai, Chengye
    Fu, Liangcai
    Jiao, Wenbin
    Wang, Huixian
    Gao, Ming
    Su, Chang
    Ma, Jun-Heng
    Xu, Yan
    Huang, Chao-Chao
    Zhang, Qing
    Ni, Shaonan
    Zhao, Maosheng
    Guo, Lixian
    Ji, Li
    Yang, Hanyu
    Zhao, Yuliang
    Li, Chunlei
    Lu, Xiang
    Su, Yu-Wen
    Li, Qi
    VACCINE, 2024, 42 (07) : 1561 - 1570
  • [35] Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer
    Li, Tong
    Song, Rui
    Wang, Jingjie
    Zhang, Jianbo
    Cai, Hongxing
    He, Hongmei
    Hu, Wei
    Yu, Dajun
    Wang, Chuanhu
    Pan, Qingbo
    Peng, Mingli
    Ren, Hong
    Zhu, Peng
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 122 : 874 - 884
  • [36] Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV: A cross-sectional study
    Cai, Shaohang
    Liao, Guichan
    Yu, Tao
    Gao, Qiqing
    Zou, Lirong
    Zhang, Huan
    Xu, Xuwen
    Chen, Juanjuan
    Lu, Aili
    Wu, Yingsong
    Li, Baisheng
    Peng, Jie
    JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (09) : 4224 - 4233
  • [37] Acceptance, safety, and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in patients with primary biliary cholangitis
    Li, Haolong
    Wang, Xu
    Wang, Siyu
    Feng, Xinxin
    Wang, Li
    Li, Yongzhe
    HELIYON, 2024, 10 (07)
  • [38] Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India A Phase 2-3 Randomized Clinical Trial
    Gunale, Bhagwat
    Kapse, Dhananjay
    Kar, Sonali
    Bavdekar, Ashish
    Kohli, Sunil
    Lalwani, Sanjay
    Meshram, Sushant
    Raut, Abhishek
    Kulkarni, Praveen
    Samuel, Clarence
    Munshi, Renuka
    Gupta, Madhu
    Plested, Joyce S.
    Cloney-Clark, Shane
    Zhu, MingZhu
    Pryor, Melinda
    Hamilton, Stephanie
    Thakar, Madhuri
    Shete, Ashwini
    Dharmadhikari, Abhijeet
    Bhamare, Chetanraj
    Shaligram, Umesh
    Poonawalla, Cyrus S.
    Mallory, Raburn M.
    Glenn, Gregory M.
    Kulkarni, Prasad S.
    JAMA PEDIATRICS, 2023, 177 (09) : 911 - 920
  • [39] Antibody response with SARS-CoV-2 inactivated vaccine (CoronaVac) in Turkish geriatric population
    Bas, Arzu Okyar
    Hafizoglu, Merve
    Akbiyik, Filiz
    Oytun, Merve Guner
    Sahiner, Zeynep
    Ceylan, Serdar
    Unsal, Pelin
    Dogu, Burcu Balam
    Cankurtaran, Mustafa
    Cakir, Banu
    Unal, Serhat
    Halil, Meltem Gulhan
    AGE AND AGEING, 2022, 51 (05)
  • [40] Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis
    Medeiros-Ribeiro, Ana Cristina
    Bonfiglioli, Karina Rossi
    Domiciano, Diogo Souza
    Shimabuco, Andrea Yukie
    da Silva, Henrique Carrico
    Saad, Carla G. S.
    Yuki, Emily Figueiredo Neves
    Pasoto, Sandra Gofinet
    Renner Araujo, Carlo Scognamiglio
    Nakai, Tatiane Lie
    Silva, Clovis Artur
    Pedrosa, Tatiana
    Kanda Kupa, Leonard de Vinci
    Rodrigues Silva, Matheus Santos
    Moreira Balbi, Guilherme Guimaraes
    Kallas, Esper Georges
    Aikawa, Nadia Emi
    Bonfa, Eloisa
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (05) : 710 - 719
12345